Ponatinib Evaluation And safety in Real Life CML patients failing ≥2 tyrosine kinase inhibitors: The PEARL observational study.
Fiche publication
Date publication
septembre 2018
Journal
Experimental hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GUERCI-BRESLER Agnès, Dr AME Shanti, Dr CHRETIEN Marie-Lorraine
Tous les auteurs :
Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE
Lien Pubmed
Résumé
Ponatinib represents a remarkable progress in the treatment of heavily pretreated CML and de novo Ph ALL patients despite significant toxicity in clinical trials. To date, "real-life" data remain few and the use of Ponatinib in this setting and its consequences remain mostly unknown.
Mots clés
Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, adverse effects, Cardiovascular Diseases, chemically induced, Compassionate Use Trials, Drug Resistance, Neoplasm, Female, Genes, abl, Humans, Imidazoles, adverse effects, Intention to Treat Analysis, Kaplan-Meier Estimate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, Male, Middle Aged, Patient Selection, Pragmatic Clinical Trials as Topic, Protein Kinase Inhibitors, adverse effects, Pyridazines, adverse effects, Salvage Therapy, Survival Analysis, Treatment Failure, Young Adult
Référence
Exp. Hematol.. 2018 Sep 5;: